专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090048233A1 Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination 审中-公开
标题翻译：通过组合使用它们提高Seratonin拮抗剂和NSRI，SNRI或RIMA的耐受性
公开(公告)号：US20090048233A1
公开(公告)日：2009-02-19
申请号：US12192591
申请日：2008-08-15
申请人： Srinivas RAO , Jay Kranzler , Jeffery J. Anderson
发明人： Srinivas RAO , Jay Kranzler , Jeffery J. Anderson
IPC分类号： A61K31/55 , A61K31/435 , A61K31/164 , A61K31/4525 , A61K31/5375 , A61K31/381 , A61K31/13 , A61P25/00
CPC分类号： A61K31/381 , A61K31/165 , A61K31/55 , A61K2300/00
摘要： Provided are combinations of pharmaceutical agents capable of eliciting a therapeutic effect. A first therapeutic agent in the combination has 5HT2/5HT3 antagonist and alpha-2 antagonist activity. A second therapeutic agent possesses both serotonin reuptake inhibitory activity and norepinephrine reuptake inhibitory activity or is a reversible inhibitor of monoamine oxidase A (RIMA). In some embodiments, a combination of a first therapeutic agent and a second therapeutic agent results in reduction in one or deleterious side effects associated with the first therapeutic agent, the second therapeutic agent or both. Also provided are methods of treatment employing a first therapeutic agent and a second therapeutic agent. Also provided are kits containing a first therapeutic agent, a second therapeutic agent and instructions for administering the first therapeutic agent and the second therapeutic agent.
摘要翻译：提供能够引起治疗效果的药剂的组合。该组合中的第一种治疗剂具有5HT2 / 5HT3拮抗剂和α-2拮抗剂活性。第二种治疗剂具有5-羟色胺再摄取抑制活性和去甲肾上腺素再摄取抑制活性，或者是单胺氧化酶A（RIMA）的可逆抑制剂。在一些实施方案中，第一治疗剂和第二治疗剂的组合导致减少与第一治疗剂，第二治疗剂或两者相关的一种或有害的副作用。还提供了使用第一治疗剂和第二治疗剂的治疗方法。还提供了含有第一治疗剂，第二治疗剂和用于施用第一治疗剂和第二治疗剂的说明书的试剂盒。

2. 发明授权

US4728969A Air assisted ink jet head with single compartment ink chamber 失效
标题翻译：空气辅助喷墨头与单室墨水室
公开(公告)号：US4728969A
公开(公告)日：1988-03-01
申请号：US884845
申请日：1986-07-11
申请人： Hue P. Le , Joy Roy , Ronald L. Adams , James C. Oswald , Jeffery J. Anderson
发明人： Hue P. Le , Joy Roy , Ronald L. Adams , James C. Oswald , Jeffery J. Anderson
IPC分类号： B41J2/045 , B41J2/04 , B41J2/14 , G01D15/18
CPC分类号： B41J2/14298 , B41J2/04 , B41J2002/14387 , B41J2202/02
摘要： An air-assisted drop-on-demand ink jet head 10 has a single compartment ink chamber 14 and is designed for operation over a wide range of ink drop repetition rates, including extremely high repetition rates, such as twenty kilohertz. The components included in the ink jet head have natural resonance frequencies which are greater than the desired maximum drop generation frequency of the ink jet head. In addition, the natural frequency of each of the components of the ink jet head are sufficiently different from one another to prevent intercoupling. Ink is supplied to the ink chamber 14 via a supply inlet passageway 38 which has a cross-sectional area which is sized large enough to allow the supply of ink to the ink chamber. Yet, this area is small enough so that the natural frequencies of ink in the ink inlet do not significantly alter drop generating pressure pulses in the ink chamber 14.
摘要翻译：空气辅助按需喷墨头10具有单室墨水室14，并且被设计用于在广泛的墨滴重复率下操作，包括极高的重复率，例如二十千赫兹。包括在喷墨头中的部件具有大于喷墨头的期望的最大液滴产生频率的天然共振频率。此外，喷墨头的每个部件的固有频率彼此充分地不同，以防止互耦。墨水通过供给入口通道38供应到墨室14，供应入口通道38的横截面面积大到足以允许向墨水室供应墨水。然而，该区域足够小，使得墨水入口中的油墨的固有频率不会显着改变墨水室14中产生的压力脉冲。

3. 发明申请

US20100204205A1 TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION 审中-公开
标题翻译：通过使用它们在组合中，咪达嗪和第二活性剂的耐受性
公开(公告)号：US20100204205A1
公开(公告)日：2010-08-12
申请号：US12610419
申请日：2009-11-02
申请人： Nir Barak , Yaffa Beck , Srinivas Rao , Jay D. Kranzler , Jeffery J. Anderson
发明人： Nir Barak , Yaffa Beck , Srinivas Rao , Jay D. Kranzler , Jeffery J. Anderson
IPC分类号： A61K31/55 , A61P25/18 , A61P25/24 , A61P25/22 , A61P25/06 , A61P25/02 , A61P11/00 , A61P1/00
CPC分类号： A61K31/4402 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having histamine H1 receptor agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having histamine H1 receptor agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having histamine H1 receptor agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having histamine H1 receptor agonist activity. Methods of treatment and kits for administration are also provided.
摘要翻译：通过施用具有组胺H1受体激动剂活性的试剂，可以减少用具有组合的5HT 2 / 5HT 3和α-2拮抗活性的药物进行治疗的副作用。提供了包含具有5HT2 / 5HT3和α-2拮抗活性的药剂和具有组胺H1受体激动剂活性的药剂的组合剂型。组合剂型的一些实施方案包括立即释放组分，其包含具有5HT 2 / 5HT 3和α-2拮抗活性的试剂和包含具有组胺H1受体激动剂活性的试剂的延迟释放组分。组合剂型的一些实施方案包括包含具有5HT2 / 5HT3和α-2拮抗活性的试剂的延迟释放组分和包含具有组胺H1受体激动剂活性的试剂的速释组分。还提供了治疗方法和用于给药的试剂盒。

4. 发明授权

US4331271A Sling for shoulder guns 失效
标题翻译：吊肩枪
公开(公告)号：US4331271A
公开(公告)日：1982-05-25
申请号：US236222
申请日：1981-02-19
申请人： Jeffery J. Anderson
发明人： Jeffery J. Anderson
IPC分类号： A45F3/02 , A45F5/00 , A41F15/00
CPC分类号： A45F5/00 , A45F2003/025 , A45F2200/0591 , Y10S224/913
摘要： A sling for carrying a shoulder operated gun, such as a rifle or shotgun, consists of a strap which may be attached to the rear swivel of a gun, then passed through the front swivel and over one shoulder, then diagonally downwardly across the chest to be attached to a belt at the other side of the body.
摘要翻译：用于携带肩部操作的枪（例如步枪或霰弹枪）的吊索由可以附接到枪的后部旋转件的带子组成，然后穿过前部旋转器并在一个肩部上，然后对角地向下穿过胸部连接到身体另一侧的皮带。

5. 发明申请

US20100160294A1 TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION 审中-公开
标题翻译：米他宁的耐受性和使用它们在组合中的第二活性
公开(公告)号：US20100160294A1
公开(公告)日：2010-06-24
申请号：US12637465
申请日：2009-12-14
申请人： Srinivas Rao , Jay Kranzler , Jeffery J. Anderson
发明人： Srinivas Rao , Jay Kranzler , Jeffery J. Anderson
IPC分类号： A61K31/55 , A61K31/5375 , A61K31/435 , A61K31/4402 , A61K31/4164 , A61K31/135 , A61K31/138 , A61P25/18 , A61P25/24 , A61P25/22 , A61P25/06
CPC分类号： A61K31/4402 , A61K31/55 , A61K45/06 , A61K2300/00
摘要： A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having selective norepinephrine reuptake inhibitor or histamine H1 agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having selective norepinephrine reuptake inhibitor or histamine H1 agonist activity. Methods of treatment comprising administration of such a dosage form after waking are also provided. Also provided are kits for administration of the first therapeutic agent having 5HT2/5HT3 and alpha-2 antagonistic activity and the second therapeutic agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. The kits include instructions for the administration of the first therapeutic agent having 5HT2/5HT3 and alpha-2 antagonistic activity prior to bed and the second agent having selective norepinephrine reuptake inhibitory activity or histamine H1 agonist activity after waking. In some embodiments, the invention provides synergistic combinations of 5HT2/5HT3 antagonist/alpha-2 antagonist and selective norepinephrine reuptake inhibitor or histamine H1 agonist.
摘要翻译：通过施用具有选择性去甲肾上腺素再摄取抑制剂或组胺H1激动剂活性的药物，可以减少用具有组合的5HT 2 / 5HT 3和α-2拮抗活性的药物治疗的副作用。提供了包含具有5HT2 / 5HT3和α-2拮抗活性的药剂和具有选择性去甲肾上腺素再摄取抑制剂或组胺H1激动剂活性的药剂的组合剂型。组合剂型的一些实施方案包括立即释放组分，其包含具有5HT 2 / 5HT 3和α-2拮抗活性的试剂和包含具有选择性去甲肾上腺素再摄取抑制剂或组胺H1激动剂活性的试剂的延迟释放组分。组合剂型的一些实施方案包括包含具有5HT 2 / 5HT 3和α-2拮抗活性的试剂的延迟释放组分和包含具有选择性去甲肾上腺素再摄取抑制剂或组胺H1激动剂活性的试剂的速释组分。还提供了包括在醒来后施用这种剂型的治疗方法。还提供了用于施用具有5HT2 / 5HT3和α-2拮抗活性的第一治疗剂的试剂盒，以及具有选择性去甲肾上腺素再摄取抑制或组胺H1激动剂活性的第二治疗剂。试剂盒包括在睡眠前施用具有5HT2 / 5HT3和α-2拮抗活性的第一种治疗剂的说明书，以及在唤醒后具有选择性去甲肾上腺素再摄取抑制活性或组胺H1激动剂活性的第二药剂。在一些实施方案中，本发明提供5HT2 / 5HT3拮抗剂/α-2拮抗剂和选择性去甲肾上腺素再摄取抑制剂或组胺H1激动剂的协同组合。

6. 发明申请

US20090275562A1 TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION 审中-公开
标题翻译：米他宁的耐受性和使用它们在组合中的第二活性
公开(公告)号：US20090275562A1
公开(公告)日：2009-11-05
申请号：US12429958
申请日：2009-04-24
申请人： Srinivas Rao , Jay Kranzler , Jeffery J. Anderson
发明人： Srinivas Rao , Jay Kranzler , Jeffery J. Anderson
IPC分类号： A61K31/55 , A61K31/5375 , A61K31/4402 , A61P39/00
CPC分类号： A61K45/06
摘要： A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having selective norepinephrine reuptake inhibitory or histamine H1 agonist activity. In some embodiments, the invention provides synergistic combinations of 5HT2/5HT3 antagonist/alpha-2 antagonist and selective norepinephrine reuptake inhibitor or histamine H1 agonist.
摘要翻译：通过施用具有选择性去甲肾上腺素再摄取抑制剂或组胺H1激动剂活性的药物，可以减少用具有组合的5HT 2 / 5HT 3和α-2拮抗活性的药物治疗的副作用。在一些实施方案中，本发明提供5HT2 / 5HT3拮抗剂/α-2拮抗剂和选择性去甲肾上腺素再摄取抑制剂或组胺H1激动剂的协同组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式